Doctiplus - We are allways here!
Heart Disease & Cardiovascular
Weekly Report
- 114 new clinical trials registered across 10 countries.
- 8,849 trials actively recruiting patients worldwide.
- Notable trial: Implementing the 6th Generation Cardiac Troponin T (22600 patients).
- 2,205 new research papers published.
- Drug safety: Most reported effect across tracked medications (atorvastatin, lisinopril, metoprolol, amlodipine, warfarin) was Fatigue.
- No active drug recalls for tracked medications this week.
The week in numbers
Trials by country
Trials by phase
New clinical trials registered this week for Heart Disease & Cardiovascular. Each trial links to its full record on ClinicalTrials.gov where you can find eligibility criteria, locations, and contact information.
This week's new registrations
114 trials registered for Heart Disease & Cardiovascular. Each links to its full record on ClinicalTrials.gov.
| # | Trial ↓ | Phase ↕ | Status ↕ | Enrollment ↕ | Country ↕ |
|---|---|---|---|---|---|
| 01 | REstoration of Communication and LAnguage With Intracortical Microelectrodes Heart Disease & Cardiovascular · The University of Texas Health Science Center, Houston (NCT07933549) | Other | Not Yet Recruiting | 4 | United States |
| 02 | Dermal Priming in Enhancing Vaccine Immunogenicity Heart Disease & Cardiovascular · Cambridge University Hospitals NHS Foundation Trust (NCT07925996) | Other | Recruiting | 28 | United Kingdom |
| 03 | BCMA/GPRC5D Dual-Target CAR-T Cell Immunotherapy for Relapsed/Refractory Multiple Myeloma Heart Disease & Cardiovascular · Liping Dou (NCT07927842) | Phase 1 | Not Yet Recruiting | 20 | China |
| 04 | Pulsed Field Ablation for Atrial Fibrillation Under General Anesthesia Versus Remimazolam-based Deep Sedation Heart Disease & Cardiovascular · China National Center for Cardiovascular Diseases (NCT07927582) | Other | Not Yet Recruiting | 200 | N/A |
| 05 | Study to Evaluate Pharmacokinetics, Safety, and Tolerability of Subcutaneous Injections of Elamipretide in Pediatric Subjects With Barth Syndrome Heart Disease & Cardiovascular · Stealth BioTherapeutics Inc. (NCT07927972) | Phase 1 | Not Yet Recruiting | 6 | N/A |
| 06 | Mobile Application to Improve Physical Activity in Patients With Heart Failure Heart Disease & Cardiovascular · Abant Izzet Baysal University (NCT07928934) | Other | Not Yet Recruiting | 82 | N/A |
| 07 | Feasibility Of Sleep Treatment Education in Stroke Rehabilitation Settings Heart Disease & Cardiovascular · University of Oxford (NCT07934485) | Other | Recruiting | 80 | United Kingdom |
| 08 | Impact of Atrial Fibrillation Prediction Model on Prescribing Oral Anti-Coagulation in Patients With Cryptogenic Stroke Heart Disease & Cardiovascular · Samir Saba (NCT07934511) | Other | Not Yet Recruiting | 100 | United States |
| 09 | Natriuresis With Acetazolamide or SGLT2 Inhibitors Added to Intravenous Loop Diuretics in Decompensated Heart Failure Heart Disease & Cardiovascular · Universidade do Porto (NCT07926958) | Phase 4 | Active Not Recruiting | 68 | Portugal |
| 10 | Prospective Cohort Study of Patients Undergoing Coronary Angiography in Vorarlberg, Austria Heart Disease & Cardiovascular · Vorarlberg Institute for Vascular Investigation and Treatment (NCT07932327) | Other | Recruiting | 2,000 | Austria |
| 11 | Long-Term Sequential Dual Antiplatelet Therapy Based on Cilostazol in Symptomatic Intracranial Arterial Stenosis Heart Disease & Cardiovascular · Second Affiliated Hospital of Soochow University (NCT07932639) | Phase 4 | Recruiting | 480 | China |
| 12 | Implementing the 6th Generation Cardiac Troponin T Heart Disease & Cardiovascular · Rasmus Bo Hasselbalch (NCT07936630) | Other | Recruiting | 22,600 | Denmark |
| 13 | Prevalence, Risk Factors, and Clinical Outcomes of Valvular Heart Disease Heart Disease & Cardiovascular · Beijing Anzhen Hospital (NCT07934641) | Other | Enrolling By Invitation | 12,000 | China |
| 14 | Integrated PET/MR Assessment of Brain Recovery After Recanalization of Non-Acute Atherosclerotic MCA Occlusion Heart Disease & Cardiovascular · Qianfoshan Hospital (NCT07927569) | Other | Recruiting | 15 | China |
| 15 | Cardiac Function After Aortic Coarctation Stenting Heart Disease & Cardiovascular · Assiut University (NCT07925970) | Other | Not Yet Recruiting | 80 | N/A |
| 16 | Gryrotonic Training in Behcet-diseased Elders With Breast Cancer Heart Disease & Cardiovascular · Cairo University (NCT07929116) | Other | Recruiting | 40 | Egypt |
| 17 | Manual Lymphatic Drainage Versus Classical Massage on Heart Responses and Mood in Hemodialysis Heart Disease & Cardiovascular · Mersin University (NCT07932483) | Other | Not Yet Recruiting | 60 | Turkey (Türkiye) |
| 18 | Focal Pulsed Field Ablation of Ventricular Tachycardia Heart Disease & Cardiovascular · Sana Hanse Hospital Wismar (NCT07929545) | Other | Enrolling By Invitation | 100 | Germany |
| 19 | Fetal Embolization for Severe Vein of Galen Malformation - A Feasibility and Safety Trial Heart Disease & Cardiovascular · Michael A Belfort (NCT07927725) | Other | Not Yet Recruiting | 10 | United States |
| 20 | Unipolar Voltage-Guided Substrate Modification Plus Pulsed Field Ablation Pulmonary Vein Isolation Versus Pulmonary Vein Isolation Alone in Persistent Atrial Fibrillation Heart Disease & Cardiovascular · China National Center for Cardiovascular Diseases (NCT07926854) | Other | Not Yet Recruiting | 294 | China |
| 21 | Intensive Glycemic Control Combined With Brolucizumab for Diabetic Macular Edema Heart Disease & Cardiovascular · The Fourth Affiliated Hospital of Zhejiang University School of Medicine (NCT07937163) | Other | Not Yet Recruiting | 100 | N/A |
| 22 | Viscoelastic Coagulation Monitoring for Early Identification of Sepsis: The VISION II Study Heart Disease & Cardiovascular · Hellenic Institute for the Study of Sepsis (NCT07927621) | Other | Not Yet Recruiting | 400 | Greece |
| 23 | Cerebral Monitoring and Postoperative Delirium in Pediatric Cardiac Surgery Heart Disease & Cardiovascular · Universitas Indonesia (NCT07923942) | Other | Completed | 42 | Indonesia |
| 24 | Carotid Ultrasound-based Assessment of Maternal Hemodynamics to Guide HYpertension Treatment in PREgnancy - Pilot Study Heart Disease & Cardiovascular · Assistance Publique - Hôpitaux de Paris (NCT07932171) | Other | Not Yet Recruiting | 200 | France |
| 25 | Gut Microbial Metabolites and Intestinal Permeability in Patients With Severe Tricuspid Regurgitation Undergoing Transcatheter Tricuspid Valve Intervention Heart Disease & Cardiovascular · Heart and Diabetes Center North-Rhine Westfalia (NCT07933198) | Other | Recruiting | 150 | Germany |
| 26 | Handheld Fan Direction for Breathlessness in Chronic Heart and Lung Disease Heart Disease & Cardiovascular · Alexandria University (NCT07930390) | Other | Not Yet Recruiting | 129 | Egypt |
| 27 | Evaluation of the Predictive Value of Microemboli Detected by Robotic Transcranial Doppler for the Occurrence of an Acute Ischemic Stroke or Left Ventricular Thrombus in STEMI Patients With Left Ventricular Dysfunction Heart Disease & Cardiovascular · CHC Montlegia (NCT07932080) | Other | Not Yet Recruiting | 116 | N/A |
| 28 | Perioperative Limb Oxygenation Monitoring in Patients With CLTI Heart Disease & Cardiovascular · Belarusian State Medical University (NCT07931768) | Other | Recruiting | 120 | Belarus |
| 29 | Melatonin in Stroke Heart Disease & Cardiovascular · King Edward Medical University (NCT07932444) | Other | Active Not Recruiting | 130 | Pakistan |
| 30 | Single-Arm Trial of Carotid Stenting for Carotid Stenosis (Timing Trial) Heart Disease & Cardiovascular · Suzhou Zenith Vascular SciTech Limited (NCT07934563) | Other | Not Yet Recruiting | 208 | China |
| 31 | Use of an AI-powered Mobile Health App in Assessing and Training Oral Motor Functions Heart Disease & Cardiovascular · The Hong Kong Polytechnic University (NCT07931898) | Other | Recruiting | 405 | Hong Kong |
| 32 | Effects of Instrument-Assisted Soft Tissue Mobilization (IASTM) Along With Conventional Physical Therapy on Upper Limb Function, Strength, Range of Motion, and Spasticity in Patients With Subacute Stroke. Heart Disease & Cardiovascular · Ibadat International University, Islamabad (NCT07937098) | Other | Recruiting | 46 | Pakistan |
| 33 | LATAM AF Ablation Registry Heart Disease & Cardiovascular · Latin American Heart Rhythm Society (NCT07924202) | Other | Not Yet Recruiting | 1,600 | N/A |
| 34 | Study of Fosfomycin-containing Antibiotic Regimens for the Treatment of Infective Endocarditis in Clinical Practice Heart Disease & Cardiovascular · Ente Ospedaliero Ospedali Galliera (NCT07930104) | Other | Not Yet Recruiting | 120 | N/A |
| 35 | The Effectiveness of Wearable Technology-Supported Gamification in Reducing Pain and Anxiety During Medical Procedures in Children: A Randomized Controlled Trial Heart Disease & Cardiovascular · Bulent Ecevit University (NCT07930962) | Other | Enrolling By Invitation | 60 | Turkey (Türkiye) |
| 36 | Health Assessment in People With Severe Mental Illness Heart Disease & Cardiovascular · University of the Basque Country (UPV/EHU) (NCT07931456) | Other | Recruiting | 275 | Spain |
| 37 | High-Intensity Interval Versus Aerobic Training for Patient-Reported Outcomes in Women With Heart Failure. Heart Disease & Cardiovascular · Universidad Internacional Isabel I de Castilla (NCT07925515) | Other | Not Yet Recruiting | 36 | Spain |
| 38 | Pediatric Longitudinal Glomerular Disease: a PNRC Multi-Institutional Cohort Study Heart Disease & Cardiovascular · Pediatric Nephrology Research Consortium (NCT07931170) | Other | Recruiting | 1,000 | United States |
| 39 | Efficacy and Circuit Mechanisms of Noninvasive Brain-Computer Interface Therapy for Upper-Extremity Motor Function in Patients With Ischemic Stroke Heart Disease & Cardiovascular · Xuanwu Hospital, Beijing (NCT07924683) | Other | Not Yet Recruiting | 38 | China |
| 40 | Clinical Pharmacist-Led Cardiovascular Risk Assessment in Patients With Chronic Kidney Disease (CRICKD) Heart Disease & Cardiovascular · Marmara University (NCT07927959) | Other | Completed | 150 | Turkey (Türkiye) |
| 41 | Feasibility of Remote Blood Pressure Monitoring to Improve Management of Hypertensive Disorders of Pregnancy Heart Disease & Cardiovascular · Sanford Health (NCT07930494) | Other | Not Yet Recruiting | 350 | United States |
| 42 | Gait Stability After Stroke Heart Disease & Cardiovascular · University Rehabilitation Institute, Republic of Slovenia (NCT07934849) | Other | Not Yet Recruiting | 50 | Slovenia |
| 43 | Holistic Empowerment Assistance Recovery Transformation Heart Disease & Cardiovascular · Institute for Cardiovascular Diseases Dedinje (NCT07927751) | Other | Recruiting | 100 | Serbia |
| 44 | Leg Position-Sense Exercises to Improve Trunk Control and Standing Up From a Chair in Men With Chronic Stroke Heart Disease & Cardiovascular · Cairo University (NCT07936500) | Other | Completed | 44 | Egypt |
| 45 | Tourniquet Use in Arteriovenous Fistula Cannulation Heart Disease & Cardiovascular · Istanbul University (NCT07931209) | Other | Completed | 504 | Turkey (Türkiye) |
| 46 | Early Mineralocorticoid Receptor Antagonist Therapy for Low-Renin Essential Hypertension Heart Disease & Cardiovascular · China National Center for Cardiovascular Diseases (NCT07932145) | Phase 4 | Not Yet Recruiting | 128 | China |
| 47 | First Pass Spectral Perfusion From Photon Counting CT Heart Disease & Cardiovascular · Medical University of Silesia (NCT07925151) | Other | Enrolling By Invitation | 200 | Poland |
| 48 | A Nurse-led Structured Risk Factor Management Programme to Improve Quality of Life for Patients With Atrial Fibrillation Heart Disease & Cardiovascular · The University of Hong Kong (NCT07929259) | Other | Not Yet Recruiting | 160 | Hong Kong |
| 49 | Long-Term Sequential Dual Antiplatelet Therapy Based on Cilostazol in Symptomatic Intracranial Arterial Stenosis: A Real-World Cohort Study Heart Disease & Cardiovascular · Second Affiliated Hospital of Soochow University (NCT07935408) | Other | Recruiting | 990 | China |
| 50 | AIM2-NLRP3 Inflammasome Dual Inhibitor on hsCRP Heart Disease & Cardiovascular · Union Hospital, Tongji Medical College, Huazhong University of Science and Technology (NCT07933757) | Other | Not Yet Recruiting | 250 | China |
Adverse event reports
Adverse drug event reports compiled from the FDA's FAERS database for medications commonly prescribed for Heart Disease & Cardiovascular. These reports reflect what patients and healthcare providers have reported — they do not confirm a drug caused the effect.
Reports by drug
| Drug | Top effect | Count |
|---|---|---|
| atorvastatin | Fatigue | 1,095 |
| lisinopril | Fatigue | 1,504 |
| metoprolol | Fatigue | 1,797 |
| amlodipine | Fatigue | 2,146 |
| warfarin | Off Label Use | 241 |
Recalls & safety notices
FDA drug recall notices for medications related to Heart Disease & Cardiovascular. If your medication is listed, contact your pharmacist or visit fda.gov/safety/recalls for guidance. No recall listed does not guarantee safety — always consult your healthcare provider.
No active drug recalls for tracked medications this period.
Published research
Recently published peer-reviewed studies related to Heart Disease & Cardiovascular, sourced from PubMed and Semantic Scholar. Click any title to read the full paper, or expand the abstract for a quick summary.
| # | Study | Journal | Date | Source |
|---|---|---|---|---|
| 01 |
Centrality of the periphery: Small muscle mass to bypass O(2) transport limitations and maximize the benefits of exercise training in heart failure.
View abstractHeart failure (HF) is a complex, systemic cardiovascular condition characterized by a severe impairment in O transport to skeletal muscle that drives exercise intolerance and reduces quality of life. Although exercise training (ET) is a cornerstone of HF clinical management, patients often exhibit limited improvements in peak oxygen uptake ( ) following traditional whole-body, aerobic exercise recruiting a large muscle mass (e.g., cycling). In patients with HF, adaptations within skeletal muscle (e.g., capillarization) exert a proportionally greater influence on changes in than adaptations in cardiac performance. In this review, we discuss the mechanisms by which traditional ET prescription may be suboptimal to elicit peripheral adaptations and argue that dynamic exercise recruiting only a small muscle mass (e.g., quadriceps) may be more effective in achieving this goal. Indeed, small muscle mass exercise reduces the cardiovascular restraints imposed by the failing heart, allowing the muscle to reach much greater metabolic rates and to be exposed to much larger degrees of homeostatic perturbations, a key factor triggering adaptations in O transport and utilization at the peripheral level. The intent of this review is to discuss the influence of muscle mass on exercise tolerance and adaptations to ET in HF, with the ultimate goal of promoting the integration of small muscle mass exercise into contemporary cardiac rehabilitation programmes. |
Experimental physiology | 2026 Nov 15 | PubMed |
| 02 |
Pulmonary Vein Reconnection Burden and Extra-Pulmonary Vein Ablation During Second Catheter Ablation for Atrial Fibrillation in the Pre-Pulsed-Field Ablation Era: A Multicenter Registry.
View abstractBACKGROUND: Contemporary procedural characteristics of second catheter ablation (CA) for atrial fibrillation (AF) remain incompletely characterized. OBJECTIVE: To investigate procedural characteristics and clinical implications of pulmonary vein (PV) reconnection during second CA for AF. METHODS: We analyzed 854 patients who underwent second CA for AF between April 2021 and March 2024 at nine institutions before the clinical adoption of pulsed-field ablation. Patients were stratified according to the number of reconnected PVs identified during the procedures: none (0), single (1), and multiple (≥ 2). The primary endpoint was freedom from atrial arrhythmia recurrence, assessed using multivariable Cox proportional hazards models. RESULTS: During second CA, PV reconnections (21% per vein) were identified and re-isolated in all affected PVs. Patients with no PV reconnection accounted for 55.5% (n = 474) of the cohort and underwent extra-PV ablation more frequently than those with single (n = 146) or multiple (n = 234) reconnected PVs. During a median follow-up of 706 days, multiple reconnected PVs with subsequent re-isolation were associated with a lower risk of atrial arrhythmia recurrence than no PV reconnection. This association remained significant after multivariable adjustment (hazard ratio 0.69, 95% confidence interval 0.50-0.95; p = 0.023) and was more pronounced in patients without symptomatic heart failure (p for interaction = 0.009). Enlarged left atrial diameter, non-paroxysmal AF, and symptomatic heart failure were also independently associated with recurrence, whereas additional extra-PV ablation was not. CONCLUSION: Re-isolation of multiple reconnected PVs was independently associated with a lower risk of atrial arrhythmia recurrence after second CA for AF, particularly in patients without symptomatic heart failure. |
Journal of cardiovascular electrophysiology | 2026 Nov 15 | PubMed |
| 03 |
Finerenone in Patients with Focal Segmental Glomerulosclerosis.
View abstractBACKGROUND: Mineralocorticoid receptor overactivation is implicated in podocyte injury and glomerulosclerosis. In a prespecified analysis of the FIND-CKD trial, we examined the efficacy and safety of finerenone in participants with focal segmental glomerulosclerosis (FSGS). METHODS: The FIND-CKD trial randomized 1584 adults with nondiabetic CKD (eGFR ≥25 to <60 ml/min/1.73 m2 and urinary albumin-to-creatinine ratio [UACR] ≥200 to <500 mg/g, or eGFR ≥25 to <90 ml/min/1.73 m2 and UACR ≥500 to ≤3500 mg/g) on stable renin-angiotensin system inhibition, 1:1 to finerenone (10 or 20 mg) or placebo. Reported outcomes include total eGFR slope (baseline to month 32; FIND-CKD primary outcome), a kidney composite (sustained ≥57% eGFR decline from baseline or kidney failure; FIND-CKD secondary outcome), changes in urinary protein-to-creatinine ratio (UPCR; exploratory outcome), and adverse events (safety outcome). RESULTS: Among the 215 participants with FSGS, mean (SD) baseline eGFR was 45 (17) ml/min/1.73 m2, and median (Q1, Q3) UPCR was 1427 (947, 2120) mg/g; 50% each had primary (n=108) and secondary (n=107) FSGS. Finerenone reduced the total eGFR slope versus placeboby 1.3 ml/min/1.73 m2/year (95% CI, 0.5-2.2; P=0.002). This effect was consistent among the 167 (78%) participants with a biopsy-proven FSGS diagnosis (1.4 ml/min/1.73 m2/year), and among participants with primary or secondary FSGS (P-interaction 0.84). Finerenone yielded a hazard ratio of 0.58 (95% CI, 0.30-1.15) versus placebo for the kidney composite outcome. From baseline to month 12, finerenone lowered UPCR by 41% (95% CI, 26%-53%) versus placebo and increased the likelihood of achieving UPCR <700 mg/g (odds ratio at month 12: 6.8 [95% CI, 3.0-17.2]). A post hoc exploratory proteomics analysis showed that finerenone versus placebo reduced markers of fibrosis, inflammation, and components of the filtration barrier. Hyperkalemia-related adverse events occurred in 15 (15%) and 23 (20%) participants assigned to finerenone or placebo, respectively. CONCLUSIONS: Finerenone was well-tolerated and preserved kidney function, lowered proteinuria, and reduced markers of fibrosis, inflammation, and components of filtration barrier in FIND-CKD participants with FSGS. |
Journal of the American Society of Nephrology : JASN | 2026 Nov 15 | PubMed |
| 04 |
Spatiotemporal Distribution and Projections to 2050 of the Disease Burden of Early-Onset Chronic Diseases Attributable to Low Physical Activity: A Global Burden of Disease Study.
View abstractBACKGROUND: Low physical activity is a modifiable risk factor for non-communicable diseases, but its contribution to early-onset chronic disease burden remains insufficiently quantified. We estimated global, regional, and national burdens of selected early-onset chronic diseases attributable to low physical activity from 1990 to 2021 and projected burden to 2050. METHODS: Using Global Burden of Disease (GBD) 2021 estimates for 204 countries and territories, we quantified disability-adjusted life years (DALYs) and age-standardized DALY rates (ASDRs) attributable to low physical activity for cancer, cardiovascular disease, diabetes mellitus, and chronic kidney disease among adults aged 25-49 years. Because GBD low physical activity exposure estimates are mainly modeled for adults aged ≥25 years, individuals aged 15-24 years were not included in the risk-attributable analyses. Trends, Socio-demographic Index (SDI)-related inequality, and future burden were assessed using estimated annual percentage changes (EAPCs), inequality indices, and Bayesian age-period-cohort modeling. RESULTS: Global DALYs attributable to low physical activity increased by 94.2%, from 686,847 in 1990 to 1.33 million in 2021. ASDR increased from 25.3 to 33.8 per 100,000 population (EAPC = 0.84; 95% confidence interval (CI) 0.70-0.97). Diabetes mellitus and chronic kidney disease showed the fastest ASDR increases, whereas cardiovascular disease and cancer showed no statistically robust trends. In 2021, regional ASDRs varied more than 11-fold, were highest in Oceania, and were higher among females and in middle-SDI settings. Absolute inequality widened, while relative inequality remained uncertain. By 2050, DALYs are projected to reach 1.76 million. CONCLUSION: Early-onset chronic disease burden attributable to low physical activity has increased substantially and unevenly. Targeted physical activity strategies for young and working-age adults are needed to reduce preventable future burden. |
Sports medicine - open | 2026 Nov 15 | PubMed |
| 05 |
Atrial Fibrillation During Zanubrutinib Treatment in Chronic Lymphocytic Leukemia With a Historical Ibrutinib Control.
View abstractINTRODUCTION: Atrial fibrillation (AF) complicates Bruton tyrosine kinase inhibitor therapy in chronic lymphocytic leukemia. METHODS: We retrospectively evaluated 679 zanubrutinib-treated patients across 52 Italian centers, with 354 historical ibrutinib-treated controls. Shanafelt AF scores were assessed. RESULTS: Nine zanubrutinib-treated patients developed AF (1.33%) during median treatment of 15.5 months, versus 42 historical controls (11.9%) over median observation of 25 months. Five zanubrutinib events occurred among patients scoring ≥ 5. No affected patients experienced embolic or bleeding complications. CONCLUSION: AF was uncommon during zanubrutinib treatment, even in the higher-risk subgroup. Historical comparisons remain limited, and exploratory score findings require confirmation with longer follow-up. TRIAL REGISTRATION: The authors have confirmed clinical trial registration is not needed for this submission. |
EJHaem | 2026 Dec | PubMed |
| 06 |
Trimethylamine N-Oxide (TMAO), Inflammation, and Cardiovascular Risk Factors in Adults With Overweight and Obesity: Impact of Fresh Watermelon Consumption in a Randomized Controlled Crossover Trial.
View abstractElevated trimethylamine N-oxide (TMAO) levels are associated with increased cardiovascular disease (CVD) risk. Watermelon consumption has been shown to improve cardiovascular function by favorably modulating lipid profiles and endothelial function. However, its impact on circulating TMAO levels remains unknown. This study examined the effects of daily watermelon consumption on TMAO and other cardiovascular risk markers in adults with overweight and obesity. In this randomized crossover clinical trial, 32 participants (16 men, 16 women; mean age 25.6 ± 6.0 years; mean BMI 29.0 ± 3.7 kg/m) consumed 330 g/day of fresh watermelon (100 kcal) or an isocaloric control (low-fat cookies, LFC) for 4 weeks, separated by a 4-week washout period. Body weight and BMI changed numerically during the watermelon intervention, but these changes were not statistically significant ( = 0.056 and = 0.070, respectively). TMAO concentrations decreased significantly from baseline following watermelon consumption ( = 0.005); however, the difference between the watermelon and LFC interventions at week 4 was not statistically significant ( = 0.091). Triglycerides and LDL cholesterol were significantly reduced following the watermelon intervention ( < 0.05). ICAM-1 levels were numerically, but not statistically significantly, lower after watermelon consumption ( = 0.083). Inflammatory markers TNF-α and IL-1β decreased significantly following the watermelon intervention ( < 0.05). Total antioxidant capacity (TAC) increased compared to LFC ( = 0.022). In conclusion, TMAO and selected cardiometabolic risk markers showed favorable within-intervention changes during the watermelon period; however, the between-intervention difference in TMAO was not statistically significant, although a numerical difference was observed. These exploratory findings require confirmation in larger, adequately powered studies. The study was registered at clinicaltrials.gov (NCT06323070). |
Food science & nutrition | 2026 Nov | PubMed |
| 07 |
Role of the Tregs-Endothelial Cell Interaction Network in Immune Microenvironment Remodeling and Targeted Intervention in Cardiovascular Diseases.
View abstractThe pathogenesis of cardiovascular disease (CVD) involves immune and metabolic remodeling of the vascular microenvironment, in which interactions between regulatory T cells (Tregs) and endothelial cells are important. Tregs can support endothelial homeostasis through immunoregulatory cytokines, whereas endothelial signals may influence Treg activity. This network has context-dependent effects in CVD: Tregs suppress inflammation, preserve endothelial barrier integrity, and promote repair, whereas Treg dysfunction, metabolic dysregulation, or age-related changes can impair endothelial function and accelerate disease progression. This review examines how glycolysis-lactate signaling, hypoxic metabolic adaptation, mitochondrial dysfunction, and redox imbalance shape Treg-endothelial crosstalk and immune microenvironment remodeling in CVD. We also discuss molecularly targeted interventions, cell-based and engineering approaches, and metabolic therapies directed at this network. Finally, we consider how spatial and single-cell multi-omics can identify disease-associated Treg and endothelial states, map their interactions, and link transcriptional programs to metabolic dysfunction. This metabolic perspective may guide mechanistic studies and the development of targeted therapies for CVD. |
Drug design, development and therapy | 2026 | PubMed |
| 08 |
Ultrasound-Guided Pudendal Nerve Block in Elderly Pelvic Organ Prolapse Surgery: Impact on Anesthetic Consumption and Postoperative Recovery-A Randomized Clinical Trial.
View abstractBACKGROUND: Nerve block is often used for multimodal analgesia. Surgeries for pelvic organ prolapse (POP) in elderly patients are focused on the perineal area, where pudendal nerve block (PNB) can provide analgesia or anaesthesia. There are limited studies on PNB in POP surgery, mainly addressing postoperative pain relief. This prospective randomized controlled trial examined the impact of ultrasound-guided PNB on intraoperative medication and postoperative recovery in elderly POP surgery patients. METHODS: Patients aged 60-70 undergoing total vaginal hysterectomy (with or without sacral fixation/colporrhaphy) under general anesthesia were randomized into two groups: PNB (pudendal nerve block) and NPNB (no pudendal nerve block). Anesthesia was induced with target-controlled infusions of remifentanil (3 ng/mL) and propofol (3 µg/mL). The study compared intraoperative anesthetic doses, hemodynamic changes, cardiovascular drug needs, wakefulness time, and post-op recovery quality between the groups. RESULTS: 58 patients completed the study. The PNB group required significantly less remifentanil (386.6 ± 239.1 µg vs 563.1 ± 235.7 µg, p = 0.005) and propofol (645.5 ± 315.2 mg vs 804.2 ± 297.2 mg, p = 0.028) compared to the NPNB group. Intraoperative hemodynamics were more stable in the PNB group, with a reduced need for vasopressors. The PNB group also exhibited faster emergence, lower postoperative pain, and less oversedation,with a non-significant trend toward higher QoR-40 scores. CONCLUSIONS: Ultrasound-guided PNB in elderly POP surgery patients reduced opioid and anesthetic doses, shortened awakening time, and produced clinically favourable improvements in postoperative recovery. Larger studies are needed to confirm these benefits for postoperative rehabilitation. |
Clinical interventions in aging | 2026 | PubMed |
| 09 |
Lessons Learned from Kawasaki Disease: Current Understanding, Cardiac Inflammation and Relationship to Systemic Childhood Inflammatory Disorders.
View abstractKawasaki Disease (KD) is now recognized as the global leading cause of acquired heart disease in children. The purpose of this review is to provide an overview of what is known about KD etiology, its management strategies and sequelae, and to discuss the inflammatory pathophysiology, specifically cardiac inflammation and development of coronary artery aneurysms (CAA) in KD and how this compares with other childhood inflammatory disorders. While the presentation of KD and its cardiovascular sequelae is unique, there is overlap in the pathophysiology of other pediatric inflammatory vasculopathies. As we understand and learn more about KD, there is opportunity for further discovery of effective treatments which may have implications in other pediatric inflammatory conditions. |
Journal of inflammation research | 2026 | PubMed |
| 10 |
Construction of a machine learning-based risk prediction model for acute stroke in maintenance hemodialysis patients.
View abstractBACKGROUND: Acute stroke represents a significant complication in patients undergoing maintenance hemodialysis (MHD) and is associated with increased mortality rates in this population. This study aimed to construct a prediction model for acute stroke in these patients by using seven machine learning algorithms. METHODS: This study included 1,100 patients receiving MHD at the First Affiliated Hospital, Zhejiang University School of Medicine, between January 1, 2015, and December 31, 2024. The patients were divided into training ( = 770) and test ( = 330) sets at a 7:3 ratio. Following feature selection using least absolute shrinkage and selection operator (LASSO) regression, predictive models were developed using seven machine learning algorithms. Model performance was evaluated using the area under the receiver operating characteristic (ROC) curve (AUC), sensitivity, specificity, and the Brier score. SHapley Additive exPlanations (SHAP) were used to quantify the contribution of individual features to model predictions. A web-based prediction tool was subsequently developed using the Shiny framework in R. RESULTS: The results showed that the extreme gradient boosting (XGBoost) model performed the best in the test set, with an AUC of 0.847 (95% confidence interval (CI) [0.791-0.902]), sensitivity = 0.73, specificity = 0.83, F1-score = 0.61 and a Brier score of 0.115. The SHAP analysis identified six most important predictors, which were ranked in the descending order as follows: pre-dialysis systolic blood pressure (SBP), serum albumin level, uric acid level, hemoglobin level, C-reactive protein level, and a history of coronary heart disease. CONCLUSIONS: We successfully developed an interpretable XGBoost-based model that effectively predicts acute stroke risk in MHD patients. |
PeerJ | 2026 | PubMed |
| 11 |
Central Obesity and Estimated Coronary Heart Disease Risk Among Jordanian Women Aged 30-50 Years: A Framingham Risk Score Analysis.
View abstractBACKGROUND: Obesity is a well-established modifiable risk factor for cardiovascular disease (CVD), particularly coronary heart disease (CHD). Its high prevalence among Jordanian women aged 30-50 years highlights the need for early cardiovascular risk assessment to support targeted preventive strategies. OBJECTIVE: To estimate the 10-year risk of CHD among Jordanian women aged 30-50 years using the Framingham risk score (FRS) and to examine the associations between general obesity, central obesity, cardiometabolic risk factors, and estimated CHD risk. METHODS: A cross-sectional study was conducted among 230 Jordanian women aged 30-50 years who were recruited using a multistage cluster sampling technique. Standardized anthropometric measurements, including body weight, height, and waist circumference (WC), were obtained to calculate body mass index (BMI) and waist-to-height ratio (WHtR). Blood pressure was measured according to standardized procedures, and fasting blood samples were analyzed to determine fasting blood glucose and lipid profile parameters. Smoking status and physical activity were assessed using structured questionnaires. The 10-year risk of CHD was estimated using the FRS. Descriptive and inferential statistical analyses were performed to evaluate the associations between obesity indices and estimated CHD risk. RESULTS: General obesity was identified in 39.1% of participants, while 40.9% had central obesity based on WC (≥ 88 cm). Nearly half of the participants (47.0%) were current smokers, and 21.3% reported low levels of physical activity. According to the FRS, 66.1% of participants were classified as having low CHD risk, 16.5% as moderate risk, and 17.4% as high risk. Higher BMI and central obesity were significantly associated with elevated blood pressure, fasting blood glucose, triglyceride levels, and LDL cholesterol, as well as lower HDL cholesterol (all < 0.001). Smoking, physical inactivity, and both general and central obesity were significantly associated with an increased estimated risk of CHD. CONCLUSION: Jordanian women aged 30-50 years exhibited a substantial burden of both general and central obesity, accompanied by an increased estimated risk of CHD. These findings underscore the importance of routine cardiovascular risk assessment and comprehensive lifestyle interventions focusing on weight management, smoking cessation, and regular physical activity. Because the FRS has not been specifically validated in Jordanian women, the estimated absolute cardiovascular risk should be interpreted with caution. |
Journal of nutrition and metabolism | 2026 | PubMed |
| 12 |
Association of GH and IGF-1 Levels with Increased Carotid Intima-Media Thickness and Cardiovascular Risk Scores in Acromegaly: A Cross-Sectional Study.
View abstractPURPOSE: This study aimed to evaluate carotid intima-media thickness (CIMT), lipid abnormalities, and cardiovascular risk scores in acromegaly patients and assess their association with disease activity and growth hormone (GH)/insulin-like growth factor-1 (IGF-1) levels. METHODS: A retrospective cross-sectional study included 104 acromegaly patients (54 female, 50 male; mean age 47.1 ± 11.0 years) and 50 age-/sex-matched healthy controls. CIMT, fasting glucose, HbA1c, lipid profile, GH, and IGF-1 were measured. Ten-year cardiovascular risk was calculated using the Systematic Coronary Risk Evaluation (SCORE) algorithm. Multiple linear regression analysis was performed to identify independent correlates of CIMT; SCORE was used only for between-group comparisons and correlation analyses, not as a dependent variable in any regression model. RESULTS: Acromegaly patients had significantly higher glucose, HbA1c, total cholesterol, LDL, and triglycerides (p < 0.001), and lower HDL (43.2 vs 48.6 mg/dL, p < 0.001). CIMT and SCORE were significantly elevated (0.79 vs 0.57 mm, p < 0.001; 6.50 vs 1.80, p < 0.001). CIMT correlated with GH (R = 0.798) and IGF-1 (R = 0.618, both p < 0.001). Active disease (GH ≥ 1 ng/mL, n = 82) showed higher CIMT (0.83 vs 0.60 mm, p < 0.01) and SCORE (7.02 vs 2.62, p < 0.01) than remission (n = 22). Multiple regression identified GH (β = 0.402), IGF-1 (β = 0.323), and age (β = 0.293) as independent correlates of CIMT; the final model explained 68.4% of the variance in CIMT ( = 0.684, p < 0.001), although this value reflects the entire multivariable model rather than GH and IGF-1 alone. Traditional risk factors (BMI, glucose, lipids) showed no significant independent association (p > 0.05). CONCLUSION: Acromegaly, especially active disease, is associated with increased CIMT and cardiovascular risk. GH and IGF-1 independently correlate with subclinical atherosclerosis beyond traditional risk factors. Further longitudinal studies are needed to determine whether achieving biochemical remission translates into reduced cardiovascular risk. |
International journal of general medicine | 2026 | PubMed |
| 13 |
Maternal cardiovascular and pregnancy outcomes among pregnant patients with mechanical and bioprosthetic valves.
View abstractINTRODUCTION: Patients with mechanical heart valves in pregnancy are at a substantially higher risk of adverse maternal and fetal outcomes. Management of patients with mechanical heart valves poses a unique challenge, and strategies for anticoagulation in these patients remain controversial. The goal of this project was to determine rates of adverse maternal and perinatal outcomes in patients with mechanical valves compared to those with bioprosthetic valves, and assess outcomes in patients with mechanical valves using low molecular weight heparin and warfarin. METHODS: A retrospective query was performed using Epic Cosmos to evaluate pregnancies affected by mechanical and bioprosthetic heart valves between January 1, 2023 and January 1, 2026. Patient demographics and rates of adverse cardiac outcomes in the perinatal period, including heart failure, arrhythmia, and stroke, were assessed. The rate of anticoagulation with low molecular weight heparin and warfarin in patients with mechanical heart valves was evaluated, and cardiac and perinatal outcomes were determined and compared between groups. Rare outcomes were reported as <10 to protect patient privacy. RESULTS: Baseline demographics between patients with mechanical and bioprosthetic heart valves were similar. Rates of heart failure (22.9%) and stroke (11.7%) were significantly higher in patients with mechanical compared to bioprosthetic heart valves, though the rates of maternal arrhythmia were similar between groups. Valve thrombosis was a rare outcome for patients with mechanical valves, with fewer than 10 events in the study sample. Perinatal outcomes including preterm and cesarean delivery were similar between groups. CONCLUSION: In conclusion, mechanical heart valves are associated with high rates of heart failure and stroke in pregnancy. Rates of adverse events may be similar for patients using low molecular weight heparin compared to warfarin for anticoagulation in pregnancy. |
Pregnancy (Hoboken, N.J.) | 2026 Nov | PubMed |
| 14 |
Nanotherapeutic Strategies Targeting Senescent Microenvironment for Aging-Related Chronic Diseases.
View abstractDCellular senescence is a central driver of age-related chronic diseases, including neurodegeneration, atherosclerosis, metabolic disorders, and fibrosis. The persistent accumulation of senescent cells and their associated secretory phenotype (SASP) creates a shared microenvironmental basis for disease progression across multiple organ systems. Senolytic and senomorphic strategies targeting senescent cells have shown therapeutic promise, yet their clinical translation remains constrained by insufficient targeting specificity, off-target toxicity, and poor tissue penetration. Nanotechnology-enabled delivery systems offer a programmable approach to overcome these barriers through rationally designed carriers that enable selective recognition of senescent cells, microenvironment-responsive drug release, and enhanced tissue accessibility. This review develops an integrated framework that links nanoplatform design principles to mechanistic intervention categories and disease-specific evidence. We first outline the molecular basis of cellular senescence and its pathological roles in age-related diseases. We then systematically examine four mechanistic dimensions of nanotherapeutic intervention in the senescent microenvironment: redox homeostasis modulation, inflammatory reprogramming, senescent cell clearance, and immune surveillance reactivation. These dimensions target reactive oxygen species, pro-inflammatory cytokines, senescent cells, and immune effector cells, respectively. Representative nanoplatforms applied to neurodegenerative, cardiovascular, metabolic, musculoskeletal, and fibrotic diseases are discussed. We further analyze key translational challenges, including senescent cell heterogeneity, impaired drug delivery in aged tissues, and regulatory uncertainty. Finally, we discuss emerging directions in precision rejuvenation, offering a conceptual framework for the next generation of senescence-targeted nanotherapies. |
International journal of nanomedicine | 2026 | PubMed |
| 15 |
Incidental Detection of a Pulmonary Valve Thrombus in a 60-Year-Old Woman: A Case Report.
View abstractPulmonary valve thrombus is a rare cardiac finding, particularly when identified incidentally in a patient without established venous thromboembolism or infective endocarditis. We report the case of a 60-year-old woman who presented with atypical chest discomfort and exertional dyspnoea. She described a sensation of being unable to take an adequate breath, while her husband had noticed increased breathing effort during routine walking. She had no previous history of ischemic heart disease or cerebrovascular disease and was a lifelong non-smoker. Cardiovascular examination was unremarkable, with normal blood pressure and oxygen saturation. Transthoracic echocardiography initially demonstrated no significant structural cardiac abnormalities or valvular pathology. CT coronary angiography, performed to investigate her symptoms, demonstrated no flow-limiting coronary artery disease but incidentally identified a filling defect associated with the pulmonary valve. Dedicated CT pulmonary angiography excluded pulmonary embolism but confirmed the pulmonary valve lesion. Cardiac MRI demonstrated a mass associated with the pulmonary valve, with appearances most consistent with thrombus. There was no clinical, laboratory, or imaging evidence of infective endocarditis. The patient was treated with warfarin anticoagulation. Follow-up CT pulmonary angiography after three months demonstrated complete resolution of the pulmonary valve lesion, supporting the diagnosis of thrombus. This case highlights the importance of considering pulmonary valve thrombus in the differential diagnosis of an incidentally detected valvular mass and demonstrates the value of multimodality cardiac imaging in differentiating thrombus from infective vegetation and benign valvular tumours. |
Cureus | 2026 Nov | PubMed |
| 16 |
Phenotypic Presentation of Atypical Familial Partial Lipodystrophy in a Patient With a Rare Mutation in the LMNA Gene: A Case Report and Literature Review.
View abstractBACKGROUND: Variants in the gene are classically associated with familial partial lipodystrophy type 2 (FPLD2/Dunnigan syndrome). However, certain mutations produce severe multisystemic phenotypes that may mimic congenital generalized lipodystrophy (CGL). This case adds to the literature by delineating the distinct syndromic expression of the p.Arg349Trp variant and underscoring the need for early recognition to guide cardiovascular and renal surveillance. CLINICAL FINDINGS: A 41-year-old woman presented to a specialized diabetes clinic serving low-income populations with severe lipoatrophy of the face and limbs, relative preservation of truncal adiposity, refractory diabetes, severe hypertriglyceridemia, arterial hypertension, and heart failure. Due to the pattern of lipodystrophy, severe systemic involvement, and absence of compensatory cervicofacial fat accumulation, CGL (Berardinelli-Seip syndrome) was initially suspected. DIAGNOSES INTERVENTIONS AND OUTCOMES: Next-generation sequencing identified a heterozygous pathogenic variant, c.1045C>T (p.Arg349Trp). At baseline, the patient presented with established proteinuric nephropathy, severe hypertriglyceridemia, and cardiovascular disease. Following multidisciplinary care and an optimized pharmacological protocol, transient improvement in metabolic and glycemic profiles was achieved. However, despite good therapeutic response, socioeconomic barriers disrupted access to high-cost medications, and she deteriorated to cardiovascular and hepatic failure, dying from cardiogenic shock and sepsis of abdominal origin in less than 2 years of follow-up. CONCLUSION: This case highlights the high clinical severity of the p.Arg349Trp variant. Recognizing it as a distinct syndromic entity is crucial to prevent diagnostic delays, enabling timely cardiovascular and renal surveillance, particularly in resource-limited settings where treatment interruptions can have fatal consequences. |
Case reports in endocrinology | 2026 | PubMed |
| 17 |
Dapagliflozin transfer in breast milk may be clinically insignificant-An opportunity for optimization of evidence-based management of heart failure in postpartum patients.
View abstractBACKGROUND: Dapagliflozin (DAPA), a sodium-glucose co-transporter inhibitor (SGLT2i), has been shown to prevent the development of heart failure and slow the progression of pre-existing heart failure; however, there are limited data published to demonstrate the safety of postpartum lactating individuals taking SGLT2is. METHODS: Lactating patients received two oral doses of 10 mg DAPA over a 48-h period. Breast milk and plasma were collected 2 h after the second dose. Samples were processed via liquid chromatography mass spectrometry (LCMS) analysis. Breast milk concentrations of DAPA were divided by plasma concentrations of DAPA (in ng/mL). The absolute (AID; i.e., daily infant dose) and relative infant doses (RID) were performed. An RID of 10% was considered the limit of acceptable exposure. RESULTS: Three of four participants were able to produce enough sample for assessment. Across three samples, the mean DAPA concentrations in plasma and breast milk were 77.6 ± 10.2 and 16.8 ± 3.1 ng/mL, respectively. Mean AID was 8.04 × 10± 2.50 × 10 mg/day and the mean RID was 7.73 ± 3.9%. CONCLUSIONS: This study demonstrates that human breast milk collected at peak anticipated maternal concentrations of DAPA has a mean RID below 10%. This is the first report of human transfer levels for DAPA, generating preliminary lactation-specific pharmacokinetic data that are essential to support evidence-based treatment of breastfeeding individuals and reduce disparities in their representation within cardiovascular therapeutic research. |
Pregnancy (Hoboken, N.J.) | 2026 Nov | PubMed |
| 18 |
Effect of Different Single-Session Durations of Intermittent Pneumatic Compression on the Prevention of Deep Vein Thrombosis in Postoperative ICU Patients: A Randomized Controlled Trial.
View abstractBACKGROUND Deep vein thrombosis (DVT) is a common and potentially life-threatening complication in postoperative ICU patients. Intermittent pneumatic compression (IPC) is widely used for mechanical thromboprophylaxis; however, the optimal single-session duration of IPC remains unclear. This randomized controlled trial aimed to evaluate the efficacy of different single-session durations of IPC for preventing DVT in postoperative ICU patients. MATERIAL AND METHODS This prospective randomized controlled trial enrolled 138 patients who were randomized into 3 groups (n = 46 each) receiving IPC 3 times daily, with single-session durations of 40 minutes, 2 hours, or 6 hours. DVT incidence, coagulation parameters (D-dimer [mg/L] and fibrinogen [FIB; g/L]), and adverse events were compared on postoperative days 3 and 5. RESULTS Baseline characteristics were comparable among groups (P>0.05). The 6-hour group had a DVT incidence of 0% on both days, significantly lower than those in the 40-minute (15.21% and 32.61%) and 2-hour (8.70% and 34.78%) groups (P<0.05). No significant intergroup differences in D-dimer levels were observed (P>0.05); FIB levels significantly differed only on day 3 (P<0.05). Adverse events occurred in 6 patients (13.04%) in the 6-hour group, whereas none occurred in the other 2 groups. CONCLUSIONS Although 6-hour single-session IPC provides the most effective DVT prevention, it is associated with a higher risk of skin-related adverse events. Shorter, more frequent IPC (40 minutes or 2 hours per session, 3 times daily) may represent a preferable strategy for postoperative ICU patients due to its balance of efficacy, safety, and clinical feasibility. |
Medical science monitor : international medical journal of experimental and clinical research | 2026 Nov 15 | PubMed |
| 19 |
Perioperative management of aortic root thrombus following HeartMate 3 implantation: review of the literature.
View abstractAortic root thrombosis (ART) is an increasingly recognized complication in patients supported with continuous-flow left ventricular assist devices (LVADs), although its incidence, prognosis, and optimal management remain poorly defined. We report 2 cases of early, asymptomatic ART detected on postoperative day 2 by routine transthoracic echocardiography after HeartMate 3 implantation. In both cases, ART developed in the setting of a persistently closed aortic valve and was identified before embolic complications occurred. Both patients were successfully managed with intensified anticoagulation, temporary pump speed escalation to maintain valve closure, and temporary restriction of physical activity. ART resolved completely without symptomatic embolic events, invasive intervention, or antiplatelet therapy, and no recurrence was observed during follow-up. These cases and the available literature suggest that early ART may be clinically silent and underrecognized even in the contemporary HeartMate 3 era. Routine early echocardiographic surveillance may facilitate timely detection, and a conservative, physiology-guided strategy focused on anticoagulation and flow adjustment appears effective in carefully selected patients under close monitoring. |
Journal of artificial organs : the official journal of the Japanese Society for Artificial Organs | 2026 Nov 14 | PubMed |
| 20 |
A pulse oximetry warning system predicts severity of late-onset sepsis in very low birth weight neonates.
View abstractBACKGROUND: Late-onset sepsis (LOS) causes morbidity and mortality in very-low birthweight (VLBW) neonates. We previously developed a machine learning model, the Pulse Oximetry Warning System (POWS), to predict LOS in the next 24 h. The neonatal Sequential Organ Failure Assessment (nSOFA) score predicts sepsis mortality. We hypothesized that POWS scores would differentiate severe LOS events, defined by nSOFA >4, from milder events. METHODS: We conducted a multicenter, retrospective cohort study including VLBW infants diagnosed with culture-confirmed LOS with continuous vital sign data available. Mixed-effects regression was used to examine the association between POWS and nSOFA. RESULTS: We analyzed 89 LOS episodes in 84 VLBW infants. Severe sepsis (nSOFA >4 within 48 h of blood culture) occurred in 27 (30%) episodes. Mean POWS scores were higher in the 24 h before severe LOS than non-severe LOS. POWS rose more steeply in the hours before sepsis diagnosis among infants with severe LOS. CONCLUSION: POWS scores, predicting risk of LOS in the next 24 h, have a significantly higher rate of rise in severe episodes as compared to less severe episodes as measured by nSOFA. This result adds to evidence that POWS could prompt earlier intervention that improves sepsis outcomes. IMPACT: Late-onset sepsis (LOS) is a leading cause of death and disability in premature infants. The Pulse Oximetry Warning System (POWS) uses continuous heart rate and oxygen saturation data to predict sepsis up to 24 h before clinical diagnosis. This study demonstrates that POWS rises more steeply before severe sepsis episodes, as defined by the neonatal Sequential Organ Failure Assessment (nSOFA) score, than before milder episodes. POWS thus may provide earlier warning of the most severe sepsis events, potentially enabling earlier intervention in this vulnerable population. |
Pediatric research | 2026 Nov 14 | PubMed |
| 21 |
The Impact of Prolonged Pre-Heart Transplantation Left Ventricular Assist Device on Post-Transplantation Outcomes.
View abstractBACKGROUND: Durable mechanical circulatory support with a left ventricular assist device (LVAD) serves as bridge to heart transplantation (HTx) in patients with advanced heart failure. LVAD therapy is associated with improved outcomes, but has inherent limitations, including device-related complications. In this study, we aimed to evaluate the impact of prolonged LVAD support in patients who underwent HTx as compared to those without LVAD support. METHOD: We retrospectively analysed 148 HTx recipients at University Medical Center Groningen, the Netherlands (2007-2023): 52 with prior LVAD support and 96 direct HTx patients. Outcomes included post-HTx survival, rejection requiring treatment, 1-year cardiac haemodynamics, and need for kidney replacement therapy. RESULTS: Median LVAD duration was 757 days (range 16-2,113). The LVAD group had fewer females (21% vs 54%; p<0.001). After a median 3.5-year follow-up, post-HTx survival was similar between groups (hazard ratio 0.83; 95% confidence interval 0.40-1.6; p=0.52). No significant differences were observed in the incidence of rejection requiring therapy (p=0.91) nor need for kidney replacement therapy (p=0.05-0.42). At 1-year post-HTx, the LVAD group showed modestly elevated pulmonary capillary wedge pressure (12.7 vs 10.6 mmHg; p=0.03) and reduced cardiac index (3.0 vs 3.3 L/min/m; p=0.03) compared to direct HTx recipients. CONCLUSIONS: Prolonged LVAD support as bridge-to-transplantation showed no statistically significant differences with direct HTx in terms of post-HTx survival, rejection rates, and renal function despite minor differences in 1-year haemodynamic parameters. |
Heart, lung & circulation | 2026 Nov 14 | PubMed |
| 22 |
Sensor-Based Force-Frequency Relation Assessment in Personalised Cardiovascular Care: An Overview.
View abstractContractility is the intrinsic ability of the heart muscle to generate force and shorten. The force-frequency relation can reveal initial alterations between normal and abnormal contractility, making it a practical index for clinical evaluation. This narrative review provides a picture of force-frequency relationship assessment, including stress echocardiography laboratories (echo labs), nuclear laboratories (nuclear labs), implantable systems, ambulatory sensors, and wearable sensors. Different approaches have been investigated in the literature, and their translation into practice could be valuable, even if challenging. With a vision for the future, real-time monitoring systems based on wearable or implantable devices, able to continuously track force-frequency changes during daily activities, could constitute a concrete opportunity for improved management of conditions such as chronic heart failure and coronary artery disease. |
Heart, lung & circulation | 2026 Nov 14 | PubMed |
| 23 |
Computed Tomography Coronary Angiography for Patients with Chest Pain: Ethnic Variation in Use, Coronary Atherosclerotic Burden, and Effect on Statin Treatment (ANZACS-QI 90).
View abstractBACKGROUND: We assessed ethnic differences in computed tomography coronary angiography (CTCA) utilisation, extent of coronary artery disease (CAD), and statin use among patients with chest pain at Middlemore Hospital, New Zealand. METHOD: Patients without prior revascularisation (n=4,519) who underwent CTCA (2020-2024) were identified from the Aotearoa New Zealand Acute Coronary Syndrome Quality Improvement (ANZACS-QI) cardiac computed tomography registry. CTCA utilisation was assessed relative to incident acute coronary syndrome (ACS) hospitalisations in each age and ethnic group, which served as a surrogate for population CAD burden. CAD extent was assessed using the segment involvement score. Statin dispensing data were obtained from the national pharmaceutical data set. RESULTS: The cohort comprised 37.8% European/Other, 13.4% Māori, 19.8% Pacific, 15.5% Indian, and 13.5% other Asian patients. Māori, Pacific, and Indian patients (mean age, 55.7, 54.8, and 54.0 years, respectively) were younger than other Asian and European/Other patients (59.2 and 60.4 years, respectively; p<0.001). CTCA utilisation among those aged <55 years was lowest among Māori and Pacific patients, intermediate among European/Other and Indian patients, and highest among other Asian patients (CTCA-to-incident-ACS ratios, 2.5, 2.2, 3.0, 3.8, and 8.0, respectively). Indian and other Asian patients were most likely to have normal coronary arteries (p<0.001), while Māori and Pacific patients had the most extensive atherosclerosis (p<0.001). Post-CTCA statin use, for equivalent disease severity, was similar across ethnicities. CONCLUSIONS: Young Māori and Pacific patients with chest pain are underinvestigated and undertreated relative to their population CAD burden. However, when CAD is identified, statin treatment is equal across ethnic groups. Therefore, CTCA facilitates equitable treatment for Māori and Pacific patients presenting with chest pain. |
Heart, lung & circulation | 2026 Nov 14 | PubMed |
| 24 |
Ocular manifestations of lipid disorders: Clinical clues for lipidologists narrative review.
View abstractBACKGROUND: Lipid disorders can produce recognizable findings in the eyelids, cornea, lens, and retina. Although many are nonspecific, selected phenotypes may signal severe hypercholesterolemia, chylomicronemia, or an inherited disorder of lipid metabolism. SOURCES OF MATERIAL: PubMed was searched from inception through August 31, 2026, using terms related to dyslipidemia, inherited lipid disorders, and ocular phenotypes. English-language human studies, clinical guidance, randomized trials, systematic reviews, cohort studies, and phenotype-defining case series were prioritized. As this was a narrative review, formal preferred reporting items for systematic reviews and meta-analyses screening, duplicate selection, risk-of-bias assessment, and meta-analysis were not performed. ABSTRACT OF FINDINGS: Clinically informative findings include xanthelasma, premature corneal arcus, lipemia retinalis, retinal hard exudates, diffuse corneal opacity with very low high-density lipoprotein cholesterol, juvenile cataracts, and pigmentary retinopathy with very low apolipoprotein B. Xanthelasma and corneal arcus may support evaluation but are not independent cardiovascular risk markers. Lipemia retinalis indicates severe chylomicronemia and should prompt assessment of pancreatitis risk. Less common phenotypes may suggest lecithin-cholesterol acyltransferase deficiency, Schnyder corneal dystrophy, cerebrotendinous xanthomatosis, or abetalipoproteinemia. Randomized trials indicate that fenofibrate can slow early diabetic retinal disease progression, although it does not replace established ophthalmic treatment. CONCLUSION: Ocular examination can provide accessible evidence of systemic lipid disturbance. Clinical value lies in distinguishing common nonspecific findings from phenotypes suggesting severe hypertriglyceridemia, possible familial hypercholesterolemia, acute retinal vascular disease, or rare inherited lipid disorders. |
Journal of clinical lipidology | 2026 Nov 11 | PubMed |
| 25 | Diuretic response in very elderly patients with acute heart failure. Author's reply. | European journal of internal medicine | 2026 Nov 14 | PubMed |
| 26 | Hepatic ChREBP Drives Cardiac Remodeling via ApoM Non-transcriptional Repression | Circulation Research | 2026 | Scholar |

